Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2015

Open Access 01-12-2015 | Research

MicroRNA-101 is a potential prognostic indicator of laryngeal squamous cell carcinoma and modulates CDK8

Authors: MingHua Li, LinLi Tian, Hui Ren, XiaoXue Chen, Yu Wang, JingChun Ge, ShuLiang Wu, YaNan Sun, Ming Liu, Hui Xiao

Published in: Journal of Translational Medicine | Issue 1/2015

Login to get access

Abstract

Background

Various microRNAs (miRNAs) negatively modulate genes that are involved in cellular proliferation, differentiation, invasion, and apoptosis. In many types of cancer, the expression profiles of these miRNAs are altered. Recently, miR-101 was identified as a tumour suppressor and was found to be expressed at low levels in various types of tumours, including prostate, breast, endometrium, and bladder cancers. However, the function(s) of miR-101 in laryngeal carcinoma remain unknown.

Methods

The expression levels of miR-101 in laryngeal squamous cell carcinoma (LSCC) tissues and cells were detected by qPCR. Cell proliferation, migration, cell cycle, and apoptosis assay were applied to assess the function(s) of miR-101 in vitro. Nude mice subcutaneous tumour model was used to perform in vivo study. Moreover, we identified Cyclin-dependent kinase 8 (CDK8) as the target of miR-101 by a luciferase assay. The possible downstream effectors of CDK8 were investigated in Wnt/β-catenin signaling pathway. Changes of CDK8, β-catenin, and cyclin D1 protein levels were analyzed by western blotting and immunohistochemical staining. The prognostic effect of miR-101 was evaluated using the Kaplan–Meier method.

Results

Expression of miR-101 was down-regulated in the LSCC tissues compared with the adjacent normal tissues. Furthermore, downregulation of miR-101 correlated with T3–4 tumour grade, lymph node metastasis, and an advanced clinical stage in the LSCC patients examined (P < 0.05). The low level of miR-101 expression was associated with poor prognosis (P < 0.05). CDK8 was identified as the target gene of miR-101 by luciferase reporter assay. Moreover, we showed that up-regulation of miR-101 expression suppressed humen LSCC Hep-2 cells proliferation and migration, and induced cell-cycle arrest. Increased expression of miR-101 induced cells apoptosis both in vitro and in vivo. Correspondingly, exogenous expression of miR-101 significantly reduced the growth of tumour in a LSCC xenograft model. Furthermore, the miR-101 level was inversely correlated with levels of CDK8, β-catenin, and cyclin D1 in western blotting assay and immunohistochemical staining assay.

Conclusions

These results indicate that miR-101 is a potent tumour repressor that directly represses CDK8 expression. Thus, detection and targeting of miR-101 may represent a novel diagnostic and therapeutic strategy for LSCC patients.
Appendix
Available only for authorised users
Literature
1.
Parkin DM, Pisani P, Ferlay J (1993) Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54:594–606CrossRefPubMed
2.
Cooper JS, Porter K, Mallin K, Hoffman HT, Weber RS, Ang KK et al (2009) National Cancer Database report on cancer of the head and neck: 10-year update. Head Neck 31:748–758CrossRefPubMed
3.
Almadori G, Bussu F, Cadoni G, Galli J, Paludetti G, Maurizi M (2005) Molecular markers in laryngeal squamous cell carcinoma: towards an integrated clinicobiological approach. Eur J Cancer 41:683–693CrossRefPubMed
4.
Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300
5.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130CrossRefPubMed
6.
7.
Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:15–20CrossRefPubMed
8.
Leaman D, Chen PY, Fak J, Yalcin A, Pearce M, Unnerstall U et al (2005) Antisense-mediated depletion reveals essential and specific functions of microRNAs in Drosophila development. Cell 121:1097–1108CrossRefPubMed
9.
Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM (2003) Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates theproapoptotic gene hid in Drosophila. Cell 113:25–36CrossRefPubMed
10.
Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843–854CrossRefPubMed
11.
Hwang HW, Mendell JT (2007) MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 96:40–44
12.
Kent OA, Mendell JT (2006) A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 25:6188–6196CrossRefPubMed
13.
14.
15.
Esquela-Kerscher A, Slack FJ (2006) Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 6:259–269CrossRefPubMed
16.
17.
Cao P, Zhou L, Zhang J, Zheng F, Wang H, Ma D et al (2013) Comprehensive expression profiling of microRNAs in laryngeal squamous cell carcinoma. Head Neck 35:720–728CrossRefPubMed
18.
Hui AB, Lenarduzzi M, Krushel T, Waldron L, Pintilie M, Shi W et al (2010) Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res 16:1129–1139CrossRefPubMed
19.
Li M, Tian L, Wang L, Yao H, Zhang J, Lu J et al (2013) Down-regulation of miR-129-5p inhibits growth and induces apoptosis in laryngeal squamous cell carcinoma by targeting APC. PLoS One 8:e77829PubMedCentralCrossRefPubMed
20.
Tian L, Zhang J, Ge J, Xiao H, Lu J, Fu S et al (2014) MicroRNA-205 suppresses proliferation and promotes apoptosis in laryngeal squamous cell carcinoma. Med Oncol 31:785CrossRefPubMed
21.
Nurul-Syakima AM, Yoke-Kqueen C, Sabariah AR, Shiran MS, Singh A, Learn-Han L (2011) Differential microRNA expression and identification of putative miRNA targets and pathways in head and neckcancers. Int J Mol Med 28:327–336PubMed
22.
Gui T, Shen K (2012) miRNA-101: a potential target for tumor therapy. Cancer Epidemiol 36:537–540CrossRefPubMed
23.
Strillacci A, Griffoni C, Sansone P, Paterini P, Piazzi G, Lazzarini G et al (2009) MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res 315:1439–1447CrossRefPubMed
24.
Hao Y, Gu X, Zhao Y, Greene S, Sha W, Smoot DT et al (2011) Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo. Cancer Prev Res (Phila) 4:1073–1083CrossRef
25.
Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B et al (2008) Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322:1695–1699PubMedCentralCrossRefPubMed
26.
Thu KL, Chari R, Lockwood WW, Lam S, Lam WL (2011) miR-101 DNA copy loss is a prominent subtype specific event in lung cancer. J Thorac Oncol 6:1594–1598CrossRefPubMed
27.
Zhang JG, Guo JF, Liu DL, Liu Q, Wang JJ (2011) MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J Thorac Oncol 6:671–678CrossRefPubMed
28.
Wang HJ, Ruan HJ, He XJ, Ma YY, Jiang XT, Xia YJ et al (2010) MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer 46:2295–2303CrossRefPubMed
29.
Konno Y, Dong P, Xiong Y, Suzuki F, Lu J, Cai M et al (2014) MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. Oncotarget 5:6049–6062PubMedCentralPubMed
30.
31.
Zhang H, Qi F, Cao Y, Chen M, Zu X (2014) Down-regulated microRNA-101 in bladder transitional cell carcinoma is associated with poor prognosis. Med Sci Monit 20:812–817PubMedCentralCrossRefPubMed
32.
Hu Z, Lin Y, Chen H, Mao Y, Wu J, Zhu Y et al (2013) MicroRNA-101 suppresses motility of bladder cancer cells by targeting c-Met. Biochem Biophys Res Commun 435:82–87CrossRefPubMed
33.
Luo C, Merz PR, Chen Y, Dickes E, Pscherer A, Schadendorf D et al (2013) MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2. Cancer Lett 341:240–247CrossRefPubMed
34.
Banerjee R, Mani RS, Russo N, Scanlon CS, Tsodikov A, Jing X et al (2011) The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. Oncogene 30:4339–4349PubMedCentralCrossRefPubMed
35.
Kim S, Xu X, Hecht A, Boyer TG (2006) Mediator is a transducer of Wnt/betacatenin signaling. J Biol Chem 281:14066–14075CrossRefPubMed
36.
Conaway RC, Sato S, Tomomori-Sato C, Yao T, Conaway JW (2005) The mammalian Mediator complex and its role in transcriptional regulation. Trends Biochem Sci 30:250–255CrossRefPubMed
37.
Knuesel MT, Meyer KD, Bernecky C, Taatjes DJ (2009) The human CDK8 subcomplex is a molecular switch that controls Mediator coactivator function. Genes Dev 23:439–451PubMedCentralCrossRefPubMed
38.
Knuesel MT, Meyer KD, Donner AJ, Espinosa JM, Taatjes DJ (2009) The human CDK8 subcomplex is a histone kinase that requires Med12 for activity and can function independently of mediator. Mol Cell Biol 29:650–661PubMedCentralCrossRefPubMed
39.
Meyer KD, Donner AJ, Knuesel MT, York AG, Espinosa JM, Taatjes DJ (2008) Cooperative activity of CDK8 and GCN5L within Mediator directs tandem phosphoacetylation of histone H3. EMBO J 27:1447–1457PubMedCentralPubMed
40.
Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I et al (2008) CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 455:547–551PubMedCentralCrossRefPubMed
41.
Morris EJ, Ji JY, Yang F, Di Stefano L, Herr A, Moon NS et al (2008) E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature 455:552–556PubMedCentralCrossRefPubMed
42.
He SB, Yuan Y, Wang L, Yu MJ, Zhu YB, Zhu XG (2011) Effects of cyclin-dependent kinase 8 specific siRNA on the proliferation and apoptosis of colon cancer cells. J Exp Clin Cancer Res 30:109PubMedCentralCrossRefPubMed
43.
Wong N, Wang X (2015) miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res 43(Database issue):D146–D152PubMedCentralCrossRefPubMed
44.
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402–408CrossRefPubMed
45.
Liu W, Saint DA (2002) A new quantitative method of real time reverse transcription polymerase chain reaction assay based on simulation of polymerase chain reaction kinetics. Anal Biochem 302:52–59CrossRefPubMed
46.
Tian L, Li M, Ge J, Guo Y, Sun Y, Liu M et al (2014) MiR-203 is downregulated in laryngeal squamous cell carcinoma and can suppress proliferation and induce apoptosis of tumours. Tumour Biol 35:5953–5963CrossRefPubMed
47.
48.
49.
Donner AJ, Ebmeier CC, Taatjes DJ, Espinosa JM (2010) CDK8 is a positive regulator of transcriptional elongation within the serum response network. Nat Struct Mol Biol 17:194–201PubMedCentralCrossRefPubMed
50.
Belakavadi M, Fondell JD (2010) CDK8 positively cooperates with mediator to promote thyroid hormone receptor-dependent transcriptional activation. Mol Cell Biol 30:2437–2448PubMedCentralCrossRefPubMed
51.
Schiano C, Casamassimi A, Rienzo M, de Nigris F, Sommese L, Napoli C (2014) Involvement of Mediator complex in malignancy. Biochim Biophys Acta 1845:66–83PubMed
52.
Grünberg S, Hahn S (2013) Structural insights into transcription initiation by RNA polymerase II. Trends Biochem Sci 38:603–611CrossRefPubMed
53.
Boube M, Joulia L, Cribbs DL, Bourbon HM (2002) Evidence for a MED of RNA polymerase II transcriptional regulation conserved from yeast to man. Cell 110(2):143–151CrossRefPubMed
54.
Napoli C, Sessa M, Infante T, Casamassimi A (2012) Unraveling framework of the ancestral Mediator complex in human diseases. Biochimie 94:579–587CrossRefPubMed
55.
56.
Paoletti AC, Parmely TJ, Tomomori-Sato C, Sato S, Zhu D, Conaway RC et al (2006) Quantitative proteomic analysis of distinct mammalian Mediator complexes using normalized spectral abundance factors. Proc Natl Acad Sci USA 103:18928–18933PubMedCentralCrossRefPubMed
57.
Zhao J, Ramos R, Demma M (2013) CDK8 regulates E2F1 transcriptional activity through S375 phosphorylation. Oncogene 32:3520–3530CrossRefPubMed
58.
Firestein R, Shima K, Nosho K, Irahara N, Baba Y, Bojarski E et al (2010) CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. Int J Cancer 126:2863–2873PubMedCentralPubMed
59.
Kaur M, Velmurugan B, Tyagi A, Agarwal C, Singh RP, Agarwal R (2010) Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through down-regulation of beta-catenin-dependent signaling. Neoplasia 12:415–424PubMedCentralCrossRefPubMed
60.
Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X et al (2011) Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 3:111–121CrossRef
61.
Kapoor A, Goldberg MS, Cumberland LK, Ratnakumar K, Segura MF, Emanuel PO et al (2010) The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature 468:1105–1109PubMedCentralCrossRefPubMed
62.
Kishi T, Ikeda A, Koyama N, Fukada J, Nagao R (2008) A refined two-hybrid system reveals that SCF(Cdc4)-dependent degradation of Swi5 contributes to the regulatory mechanism of S-phase entry. Proc Natl Acad Sci USA 105:14497–14502PubMedCentralCrossRefPubMed
63.
Chi Y, Huddleston MJ, Zhang X, Young RA, Annan RS, Carr SA et al (2001) Negative regulation of Gcn4 and Msn2 transcription factors by Srb10 cyclin-dependent kinase. Genes Dev 15:1078–1092PubMedCentralCrossRefPubMed
64.
65.
66.
Akoulitchev S, Chuikov S, Reinberg D (2000) TFIIH is negatively regulated by CDK8-containing mediator complexes. Nature 407:102–106CrossRefPubMed
67.
Liu Y, Kung C, Fishburn J, Ansari AZ, Shokat KM, Hahn S (2004) Two cyclin-dependent kinases promote RNA polymerase II transcription and formation of the scaffold complex. Mol Cell Biol 24:1721–1735PubMedCentralCrossRefPubMed
68.
Fryer CJ, White JB, Jones KA (2004) Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover. Mol Cell 16:509–520CrossRefPubMed
69.
Nelson C, Goto S, Lund K, Hung W, Sadowski I (2003) Srb10/CDK8 regulates yeast filamentous growth by phosphorylating the transcription factor Ste12. Nature 421:187–190CrossRefPubMed
70.
Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC (2005) Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr Rev 26:898–915CrossRefPubMed
71.
Katoh M, Katoh M (2007) Wnt signaling pathway and stem cell signaling network. Clin Cancer Res 13:4042–4045CrossRefPubMed
72.
Kielman MF, Rindapaa M, Gaspar C, van Poppel N, Breukel C, van Leeuwen S et al (2002) Apc modulates embryonic stem-cell differentiation by controlling the dosage of beta-catenin signalling. Nat Genet 32:594–605CrossRefPubMed
73.
Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL (2011) Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 11:558–572CrossRefPubMed
Metadata
Title
MicroRNA-101 is a potential prognostic indicator of laryngeal squamous cell carcinoma and modulates CDK8
Authors
MingHua Li
LinLi Tian
Hui Ren
XiaoXue Chen
Yu Wang
JingChun Ge
ShuLiang Wu
YaNan Sun
Ming Liu
Hui Xiao
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2015
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-015-0626-6

Other articles of this Issue 1/2015

Journal of Translational Medicine 1/2015 Go to the issue

Research

Global comparison of chromosome X genes of pulmonary telocytes with mesenchymal stem cells, fibroblasts, alveolar type II cells, airway epithelial cells, and lymphocytes

Research

Quantitative analysis of proteins of metabolism by reverse phase protein microarrays identifies potential biomarkers of rare neuromuscular diseases

Research

Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer

Research

Cyclic helix B peptide inhibits ischemia reperfusion-induced renal fibrosis via the PI3K/Akt/FoxO3a pathway

Research

Bisphenol-A plasma levels are related to inflammatory markers, visceral obesity and insulin-resistance: a cross-sectional study on adult male population

Research

Perioperative dynamics and significance of amino acid profiles in patients with cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits